[Current therapeutic possibilities for XXXX ].

@entity1 @entity6839 @entity15438 @entity1596 @entity16495 @entity2790
OBJECTIVE: to evaluate the efficacy of combination therapy with three antiglaucoma agents ( @entity15438 + @entity16495 / @entity6839 ) for @entity2790 . MATERIAL AND METHODS: The study enrolled 20 @entity1 with anterior @entity1596 complicated by intraocular pressure (IOP) elevation. Besides standard anti-inflammatory agents, the treatment included IOP-lowering instillations, namely @entity15438 2% 3 times daily and @entity6839 0.5% 2 times daily. Those @entity1 whose IOP remained uncompensated were then switched to a three-drug regimen: @entity15438 2% 3 times daily and a fixed combination of @entity16495 0.2%, an aLPHA2-receptor agonist, and @entity6839 0.5%, a 3-blocker, 2 times daily (Combigan, Allergan). IOP was measured with Maklakov tonometer three times during the day before the treatment and then three times daily while performing the two- or three-drug combination therapy. RESULTS: The mean initial IOP was 34.57 +/- 0.09 mmHg with daily fluctuations of 5.2 +/- 0.08 mmHg. After starting the unfixed combination therapy ( @entity15438 + @entity6839 ) the mean IOP decreased by 7.86 +/- 0.07 mmHg. Switching to the three-drug therapy ( @entity15438 + @entity16495 / @entity6839 ) enabled an additional decrease in IOP by 5.43 +/- 0.06 mmHg. Thus, with the new regimen the total decrease in IOP averaged 13.29 +/- 0.09 mmHg with daily fluctuations of 2.5?0.06 mmHg, which ensured that the target IOP was achieved in all @entity1 . All the drugs were well-tolerated. CONCLUSION: Combination therapy with three antiglaucoma agents in the form of two medications-- @entity15438 2% and @entity16495 / @entity6839 fixed combination (Combigan)--is shown to be effective in @entity2790 @entity1 .
